NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 58 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $0 | – | 592 | +191.6% | 0.00% | – |
| Q1 2023 | $0 | – | 203 | -1.5% | 0.00% | – |
| Q4 2022 | $0 | – | 206 | -60.8% | 0.00% | – |
| Q3 2022 | $0 | – | 525 | +147.6% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 212 | -94.2% | 0.00% | – |
| Q1 2022 | $7,000 | -83.7% | 3,663 | -59.0% | 0.00% | – |
| Q4 2021 | $43,000 | +2.4% | 8,935 | +54.5% | 0.00% | – |
| Q3 2021 | $42,000 | -38.2% | 5,782 | -22.0% | 0.00% | – |
| Q2 2021 | $68,000 | -41.9% | 7,411 | -21.8% | 0.00% | – |
| Q1 2021 | $117,000 | 0.0% | 9,483 | +14.6% | 0.00% | – |
| Q4 2020 | $117,000 | +62.5% | 8,274 | +37.0% | 0.00% | – |
| Q3 2020 | $72,000 | -61.5% | 6,039 | -46.5% | 0.00% | – |
| Q2 2020 | $187,000 | -76.1% | 11,287 | -83.6% | 0.00% | – |
| Q1 2020 | $781,000 | +25.8% | 68,674 | +36.4% | 0.00% | – |
| Q4 2019 | $621,000 | +114.9% | 50,359 | -50.2% | 0.00% | – |
| Q3 2019 | $289,000 | – | 101,178 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,386,300 | $19,547,000 | 2.55% |
| EcoR1 Capital, LLC | 3,122,704 | $44,030,000 | 2.37% |
| Redmile Group, LLC | 4,131,869 | $58,259,000 | 0.70% |
| Boxer Capital, LLC | 1,501,058 | $21,165,000 | 0.68% |
| HighVista Strategies LLC | 69,727 | $983,000 | 0.63% |
| Baker Brothers Advisors | 3,821,740 | $53,887,000 | 0.20% |
| Highland Private Wealth Management | 93,998 | $1,326,000 | 0.12% |
| Sio Capital Management, LLC | 38,312 | $540,000 | 0.11% |
| Point72 Asset Management, L.P. | 1,195,725 | $16,860,000 | 0.08% |
| Granahan Investment Management | 246,299 | $3,473,000 | 0.08% |